Julie R. Park, MD

Cancer and Blood Disorders Center, Thyroid Program, Neuroblastoma Program, Bone Tumors and Soft Tissue Tumors

On staff since October 1996

Children's Title: Bushnell, Towne and Wilkerson Endowed Chair in Pediatric Neuroblastoma and Medical Director Immunotherapy Coordinating Center

Academic Title: Professor of Pediatrics, UW School of Medicine; Associate, Clinical Research Division, Fred Hutchinson Cancer Research Center

Research Center: Center for Clinical and Translational Research

  • Biography

    Julie R. Park, MD, is attending physician at Seattle Childrens Hospital, professor in pediatrics at the University of Washington School of Medicine and associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center (FHCRC). She is director of the pediatric hematology-oncology fellowship at the University of Washington.

    Julie R. Park, MD, is attending physician at Seattle Children’s Hospital, professor in pediatrics at the University of Washington School of Medicine and associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center (FHCRC). She is medical director of Immunotherapy Coordinating Center within the Immunotherapy Integration Hub and is medical director of the Cancer and Blood Disorders Advanced Therapeutics clinical research program.

    Dr. Park’s primary research focus has been investigating novel therapies for the treatment of refractory and recurrent cancers with a specific focus on high-risk neuroblastoma, a rare but aggressive form of childhood cancer. Park is an active member of the Children’s Oncology Group Consortium and as chair of the COG Neuroblastoma Scientific Committee provides leadership for the development of neuroblastoma clinical research within COG. Within COG, she conducted a multi-center clinical trial to determine the feasibility and toxicity of a novel induction chemotherapy regimen for high risk neuroblastoma which has become the backbone induction regimen used in North America.  Within COG, Dr. Park also led a randomized clinical trial that determined the benefit of tandem transplant as consolidation therapy for high risk neuroblastoma and was instrumental in the development of chemo-immunotherapy regimen that has proven benefit for children with recurrent or refractory neuroblastoma.  In addition to COG, Dr. Park collaborates with investigators through North America as the Scientific Medical Director for the New Approaches to Neuroblastoma Therapy (NANT), developing novel targeted therapies for children with recurrent and refractory neuroblastoma.  Dr. Park also collaborates closely with Drs. Jensen and Gardner in the development and implementation of novel cellular immunotherapy approaches for children with recurrent and refractory cancers.

    • Related Pages

    • Gaining Ground on Neuroblastoma

      We helped show that two stem cell transplants, plus immunotherapy, significantly increased survival for children with high-risk neuroblastoma.

  • Patient Testimonials

    • Tracey Seattle, WA 06.22.14

      Dr. Park is my daughter's Doctor. Just saying those words bring hope. I know Dr. Park is absolutely invested in saving children's lives and that she works tirelessly at finding new ways to do so. We may have traveled off the beaten path, where treatment for my daughter is concerned, but only to find that Dr. Park has laid pavement. Not sure what the outcome for my child will be, but I know that Dr. Park is doing all she can to save her. Thank you Dr. Park.

    • Heather Redmond, WA 07.10.13

      Dr. Park did a wonderful job in her medical treatment of my daughter! We began the journey full of fears and worries, and we are so fortunate to have had the best possible outcome. I firmly believe that much of this is due to Dr. Park's wealth of experience, close monitoring and her willingness to listen to my concerns. I always feel that my daughter's best interests are Dr. Park's primary concern, and she has always been very compassionate and caring towards me - even when I was having a hard time coming to grips with what was happening. Anyone who has Dr. Park as their child's oncologist is very lucky to have her!

    Recommend Dr. Julie R. Park

  • Awards and Honors

    Award Name Award Description Awarded By Award Date
    SEATTLE'S TOP DOCTOR - 2019 Seattle Magazine 2019
    SEATTLE'S TOP DOCTOR - 2018 Seattle Magazine 2018
    Frank Oski Award American Society of Pediatric Hematology and Oncology 2018
    SEATTLE'S TOP DOCTOR - 2017 Seattle Magazine 2017
    Seattles Top Doctor 2016 Seattle Met Magazine 2016
    SEATTLE MAGAZINE TOP DOCTOR - 2016 Seattle Magazine 2016
    SEATTLE MAGAZINE TOP DOCTOR - 2015 Seattle Magazine 2015
    SEATTLE MAGAZINE TOP DOCTOR - 2014 Seattle Magazine 2014
    Seattle's Top Doc Seattle Met Magazine 2013
    Seattle Magazine Top Doctor - 2013 Seattle Magazine 2013
    Seattle Magazine Top Doctor - 2012 Seattle Magazine Top Doctor - 2012 Seattle Magazine 2012
    U.S. News Top Doctor U.S. News and World Report 2012
    Benjamin Towne Endowed Chair in Neuroblastoma Benjamin Towne Foundation 2009
    Newsweek Health: Top Cancer Doctors 2015 Newsweek 2015

  • Publications

    Other Publications

    • Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM
      Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBL0621).
      24347462 Pediatric blood & cancer, 2013 Dec. 18
    • Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H
      Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
      23901000 Cancer, 2013 Oct. 15 : 119(20)3718-26
    • Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG
      Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
      23890779 The lancet oncology, 2013 Sept. : 14(10)999-1008
    • Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA
      A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1.
      23334272 Bone marrow transplantation, 2013 July : 48(7)947-52 PMCID:PMC3638062
    • Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KM, Hogarty M, COG Neuroblastoma Committee
      Children's Oncology Group's 2013 blueprint for research: neuroblastoma.
      23255319 Pediatric blood & cancer, 2013 June : 60(6)985-93
    • Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KK
      Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.
      23440556 Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013 April : 54(4)541-8
    • Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, Jarzembowski JA, Joshi VV, Navarro S, Peuchmaur M, Shimada H
      Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
      22744966 Pediatric blood & cancer, 2013 March : 60(3)363-70 PMCID:PMC3397468
    • Moreno L, Barone G, Park JR, Pearson AD
      About the benefits of immunotherapy for high-risk neuroblastoma.
      23295791 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013 Feb. 10 : 31(5)649-50
    • Gross TG, Orjuela MA, Perkins SL, Park JR, Lynch JC, Cairo MS, Smith LM, Hayashi RJ
      Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.
      22883417 American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2012 Nov. : 12(11)3069-75 PMCID:PMC3484187
    • Glade Bender J, Blaney SM, Borinstein S, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, Park JR
      A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report.
      22791883 Clinical cancer research : an official journal of the American Association for Cancer Research, 2012 Sept. 15 : 18(18)5081-9 PMCID:PMC3445751
    • Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, Frazier J, Chau BN, Loboda A, Linsley PS, Cleary MA, Park JR, Grandori C
      Functional genomics identifies therapeutic targets for MYC-driven cancer.
      22623531 Proceedings of the National Academy of Sciences of the United States of America, 2012 June 12 : 109(24)9545-50 PMCID:PMC3386069
    • Fisher BT, Zaoutis TE, Park JR, Bleakley M, Englund JA, Kane C, Arceci RJ, Guinan E, Smith FO, Luan X, Marr KA
      Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients.
      23687575 Journal of the Pediatric Infectious Diseases Society, 2012 June : 1(2)103-111 PMCID:PMC3656552
    • Raccor BS, Claessens AJ, Dinh JC, Park JR, Hawkins DS, Thomas SS, Makar KW, McCune JS, Totah RA
      Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo.
      21976622 Drug metabolism and disposition: the biological fate of chemicals, 2012 Jan. : 40(1)54-63 PMCID:PMC3250049
    • Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KK
      Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.
      22010014 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011 Nov. 20 : 29(33)4351-7 PMCID:PMC3221519
    • Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JM
      Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.
      21340605 Cancer chemotherapy and pharmacology, 2011 Oct. : 68(4)1057-65
    • Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG
      A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.
      21671363 Pediatric blood & cancer, 2011 Aug. : 57(2)275-82 PMCID:PMC3117015
    • Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zwiebel J, Blaney SM, Adamson PC
      Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
      20606092 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010 Aug. 1 : 3623-9
    • Park JR, Eggert A, Caron H
      Neuroblastoma: biology, prognosis, and treatment.
      20113896 Hematology/oncology clinics of North America, 2010 Feb. : 65-86
    • Fong A, Park JR
      High-risk neuroblastoma: a therapy in evolution.
      19954363 Pediatric hematology and oncology, 2009 Nov. : 539-48
    • Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK
      Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
      19171709 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009 March 10 : 1290-6
    • Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, Attiyeh EF, Maris JM, Seeger RC, Reynolds CP, Matthay KK
      Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
      18937318 Pediatric blood & cancer, 2009 Jan. : 44-50
    • McCune JS, Salinger DH, Vicini P, Oglesby C, Blough DK, Park JR
      Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group.
      18927240 Journal of clinical pharmacology, 2009 Jan. : 88-102
    • Tasian SK, Park JR, Martin ET, Englund JA
      Influenza-associated morbidity in children with cancer.
      18240170 Pediatric blood & cancer, 2008 May : 983-7
    • Park JR, Eggert A, Caron H
      Neuroblastoma: biology, prognosis, and treatment.
      18242317 Pediatric clinics of North America, 2008 Feb. : 97-120, x
    • Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MC
      Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
      17299405 Molecular therapy : the journal of the American Society of Gene Therapy, 2007 April : 825-33
    • Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC
      Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
      16170157 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005 Sept. 20 : 6481-8
    • Thomson B, Park JR, Felgenhauer J, Meshinchi S, Holcenberg J, Geyer JR, Avramis V, Douglas JG, Loken MR, Hawkins DS
      Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
      15382275 Pediatric blood & cancer, 2004 Oct. : 571-9
    • Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI
      Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
      15328169 Clinical cancer research : an official journal of the American Association for Cancer Research, 2004 Aug. 15 : 5335-41
    • Bradfield SM, Douglas JG, Hawkins DS, Sanders JE, Park JR
      Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.
      15022296 Cancer, 2004 March 15 : 1268-75
    • Wright JA, Bradfield SM, Park JR, Hawkins DS
      Prolonged survival after invasive aspergillosis: a single-institution review of 11 cases.
      12679641 Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology, 2003 April : 286-91
    • Park JR, Coughlin J, Hawkins D, Friedman DL, Burns JL, Pendergrass T
      Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
      12461792 Medical and pediatric oncology, 2003 Feb. : 93-8

    Show More Hide

  • Presentations

    Presentations Title Event Location Date
    Infectious Complications of Pediatric Cancer Advanced Oncology Nursing unknown Oct. 1, 2009
    Infectious Complications of Pediatric Cancer Advanced Oncology Nursing unknown June 1, 2009
    Accessing Novel Therapies and Navigating the Maze - The Pediatric Oncologist's Perspective American Society of Clinical Oncology, Educational Session Orlando, FL June 1, 2009
    Targeting Treatment to Improve Outcomes for Childhood Cancer Circle of Care Symposium, Seattle Children’s Hospital Seattle, WA May 1, 2009
    Infectious Complications of Pediatric Cancer Advanced Oncology Nursing unknown Feb. 1, 2009
    Infectious Complications of Pediatric Cancer Advanced Oncology Nursing unknown Feb. 1, 2009

Overview

Board Certification(s)

Pediatric Hematology-Oncology

Medical/Professional School

University of Vermont College of Medicine, Burlington

Clinical Interests

Neuroblastoma, Novel therapies for recurrent and refractory cancer, Novel cellular immunotherapy 

Research Description

My research focus is to develop novel therapy for children with cancer with specific areas of focus on neuroblastoma and development of novel immunotherapy for children with relapsed and refractory cancers. The goal of my research is to translate laboratory findings into new therapies for children with cancer through close collaboration with  both investigators at Seattle Children’s Research Institute, Fred Hutch, nationally and internationally. To facilitate this goal, I am chair of the Neuroblastoma Scientific Committee within Children's Oncology Group (COG) Consortium, leading development of clinical trials for children with neuroblastoma. In addition, I oversee the development of clinical trials for recurrent and refractory high risk neuroblastoma within the New Approaches to Neuroblastoma Therapy (NANT) consortium. I also oversee the development and implementation of cellular immunotherapy clinical trials for children with relapsed and refractory cancers at Seattle Children’s Research Institute and am funded through the NIH to lead the Pediatric Consortium for Cellular ImmunoTherapy in overcoming barriers to the implementation of novel cellular therapy. Nationally, I am co-investigator with Dr. Jensen for the Stand Up to Cancer Pediatric Dream Team and a member of the scientific steering committee for the Pediatric Clinical Immunotherapy Trials Network (PedCITN) as well as site investigator for the Pediatric Early Program Clinical Trials Network, both NCI funded consortia to develop novel therapies for children with recurrent and refractory cancer.

Research Focus Area

Refractory and recurrent cancer, Sarcomas, Thyroid Cancer, Cancer biology, Cancer